Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

686
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
686
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

575
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
575
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

1.1K
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
1.1K
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

1.8K
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
1.8K
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

1.2K
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
1.2K
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

286
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
286

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mass Spectrometry Insights Into Post-Translational Modifications in Extracellular Vesicles.

Mass spectrometry reviews·2026
Same author

Association of SARS-CoV-2 infection with incident diabetes among U.S. Veterans in a prospective longitudinal cohort.

PloS one·2026
Same author

Correction: Study protocol for the: HIV enhanced access testing in emergency department program using a systems analysis and improvement approach (HEATED-SAIA) cluster randomized trial.

Implementation science communications·2026
Same author

Time to Progress Through the Latent Tuberculosis Infection Care Cascade in Primary Care.

Public health reports (Washington, D.C. : 1974)·2026
Same author

Study protocol for the: HIV enhanced access testing in emergency department program using a systems analysis and improvement approach (HEATED-SAIA) cluster randomized trial.

Implementation science communications·2026
Same author

Latent tuberculosis infection care cascade outcomes in primary care clinics in the tuberculosis epidemiologic studies consortium-III.

Annals of epidemiology·2026
Same journal

Characteristics of Children Seeking Care at School-Based Health Centers.

Journal of the American Board of Family Medicine : JABFM·2026
Same journal

An Analysis of Common Questions and Concerns of Older Adults with Multiple Chronic Conditions.

Journal of the American Board of Family Medicine : JABFM·2026
Same journal

Primary HPV Testing for Cervical Cancer Screening Among Family Medicine Educators.

Journal of the American Board of Family Medicine : JABFM·2026
Same journal

"Hard Fork" for Family Medicine - Artificial Intelligence Will Change the Way We Experience Practice.

Journal of the American Board of Family Medicine : JABFM·2026
Same journal

The Importance of Primary Care Subject Matter Experts: Output Quality in Large Language Models Prompt Engineering.

Journal of the American Board of Family Medicine : JABFM·2026
Same journal

Daily Nutrient Intake and Inflammation Among US Adults.

Journal of the American Board of Family Medicine : JABFM·2026
See all related articles

Related Experiment Video

Updated: Feb 26, 2026

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

2.3K

Factors That Influence Treatment Completion for Latent Tuberculosis Infection.

McKenna C Eastment1, Adelaide H McClintock2, Christy M McKinney2

  • 1From the Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington School of Medicine, Seattle (ME); the Division of General Internal Medicine, Department of Medicine, University of Washington School of Medicine, Seattle (AHM, AM); the Department of Oral Health Sciences, University of Washington School of Dentistry, Seattle (CMM); the Division of Pulmonary & Critical Care Medicine, Department of Medicine, University of Washington School of Medicine, Seattle (MN); and the Tuberculosis Control Program, Public Health - Seattle & King County, Seattle, Washington (MN). mceast@uw.edu.

Journal of the American Board of Family Medicine : JABFM
|July 20, 2017
PubMed
Summary
This summary is machine-generated.

Latent tuberculosis infection (LTBI) therapy completion rates were 66%. Noncompletion was linked to social factors, substance use, and charity care, with loss to follow-up being the primary reason.

Keywords:
Antitubercular AgentsIsoniazidLatent TuberculosisMotivationRetrospective StudiesRifampinRifapentine

More Related Videos

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates
10:04

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates

Published on: September 5, 2017

19.4K
Validated LC-MS/MS Panel for Quantifying 11 Drug-Resistant TB Medications in Small Hair Samples
08:54

Validated LC-MS/MS Panel for Quantifying 11 Drug-Resistant TB Medications in Small Hair Samples

Published on: May 19, 2020

8.3K

Related Experiment Videos

Last Updated: Feb 26, 2026

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

2.3K
Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates
10:04

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates

Published on: September 5, 2017

19.4K
Validated LC-MS/MS Panel for Quantifying 11 Drug-Resistant TB Medications in Small Hair Samples
08:54

Validated LC-MS/MS Panel for Quantifying 11 Drug-Resistant TB Medications in Small Hair Samples

Published on: May 19, 2020

8.3K

Area of Science:

  • Public Health
  • Infectious Diseases
  • Clinical Medicine

Background:

  • Latent tuberculosis infection (LTBI) requires treatment to prevent progression to active disease.
  • Identifying factors associated with LTBI therapy noncompletion is crucial for public health strategies.

Purpose of the Study:

  • To describe demographic, treatment, and monitoring factors associated with noncompletion of latent tuberculosis infection (LTBI) therapy.

Main Methods:

  • Retrospective cohort study of adults initiating LTBI treatment across five clinics.
  • Data abstracted included demographic, treatment, and monitoring characteristics.
  • Descriptive statistics and comparative analyses (t-tests, chi-squared tests) were used.

Main Results:

  • Overall LTBI treatment completion rate was 66%.
  • Noncompleters were more likely to be unmarried, use tobacco/alcohol, have comorbidities, and receive charity care.
  • Loss to follow-up was the most common reason for discontinuation, particularly with isoniazid-only regimens.

Conclusions:

  • Patients with factors linked to noncompletion may benefit from enhanced adherence interventions.
  • Potential interventions include improved outreach, incentives, and home visits to improve LTBI treatment completion.